Founded in 2020, iTolerance is regenerative medicine company developing a potential cure for Type 1 Diabetes that eliminates the need for chronic immunosuppression of patients.
The company’s lead program, ITOL-101, is an adjunct therapy with pancreatic islet cell implant currently in development for the treatment of or as a potential breakthrough cure for Type 1 Diabetes. As an adjunct therapy with pancreatic islet cells, the company says that ITOL-101 creates a durable, localized immune tolerance that has the potential to protect implanted islet cells from rejection by the body’s own immune system. This localized immune acceptance potentially eliminates the need for sustained immunosuppressants and allows for localized remodeling and functional engraftment. iTolerance reports that ITOL-101 has demonstrated compelling efficacy in non-human primate studies. The company plans to advance ITOL-101 towards an IND and first-in-man study.
In addition to ITOL-101, iTolerance is advancing its regenerative cell therapy platform to fuel a ‘robust’ pipeline addressing other high-value indications.
Aulos Bioscience aims to revolutionize cancer patient care through the development of pioneering Interleukin-2 therapeutics for the treatment of solid tumor cancers. Interleukin-2 or IL-2 …
Code Bio is using its novel targeted non-viral delivery platform to develop genetic medicines for serious and life-threatening diseases such as Type 1 Diabetes and …
Muna Therapeutics aims to preserve brain function and enhance resilience to neurodegenerative diseases. The company engages in the discovery and development of novel therapies that …
Glyphic Biotechnologies is an MIT spin-out aiming to accelerate the critical but slow step of sequencing new proteins, potentially cutting drug development times down by …
ImmuneID is a precision immunology company that has developed a genome-wide, high-throughput platform to provide an understanding of individual immune responses. ImmuneID's aiSPIRE platform screens billions of …
Flare uses a “switch-site based drug discovery approach” to develop a pipeline of therapeutic programs that target pivotal cancer drivers such as transcription factor dysregulation …